Compare Cassava Sciences Inc (FLNA) vs Nike Inc (NKE) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Nike (NKE) trades at $42.86, down 2.06% today, with a bearish technical signal and recent earnings beats. Revenue declined to $46.31B in 2025, with net income margin at 6.7%. The stock shows strong profitability with ROE of 22.14% but faces headwinds in China and EMEA. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting 18.5% upside.

Outlook remains cautious near-term due to sales pressure and margin compression, but long-term brand strength and digital DTC strategy offer recovery potential. Key risks include consumer demand softness and competitive pressures. The stock presents a contrarian opportunity if execution improves, supported by institutional confidence.